We attempted to determine the frequency of normal hematopoietic stem cells (HSC) and contaminating leukemic cells in mobilized peripheral blood (MPB) collected from chronic myeloid leukemia (CML) patients, intolerant of a-interferon or with interferon-resistant disease. A total of 14 MPB samples, six from patients in chronic phase (CP) and eight from patients in accelerated phase or blast crisis (AP/BC) were studied. Cytogenetic analysis of MPB collected from AP/BC patients showed that 100% of the cells were Ph+, whereas cells from four of five CP MPB were Ph-. By contrast, fluorescence in situ hybridization (FISH) analysis of CP MPB showed a mean frequency of 14.7% Ph+ cells, while AP/BC MPB contained 39.2% Ph+ cells. In an attempt to purify normal HSC, subpopulations of the MPB CD34+ cells were isolated based on expression of the Thy-1 antigen (Chnrso). The mean Ph+ cell frequency as determined by FISH within the CD34+Thy-l+ Linand CD34+Thy-I-Lin-populations from CP patients was 19.2% Unfortunately, most patients are not suitable for allogeneic BMT due to lack of an appropriate available donor or because of relatively advanced age. McGlave et a16 recently reported the results of a multicenter study that suggests autologous transplantation can prolong the survival of patients with CML. However, the persistence of leukemic cells within the marrow and peripheral blood of patients posttransplantation was evident in a majority of the survivors.6 Relapse of these patients may result from the persistence of tumor cells within the patients following intensive myeloablative therapy and/or be the result of tumor cells present in the graft. Support for the latter explanation for the CD34+Thy-lfLin-cells as compared with 1 of 133 for the Thy-1-fraction indicating a higher frequency of primitive progenitor cells in the Thy-l+ subpopulation. CD34' cell subsets from two patients were also injected into SClDhu bone assays to determine the in vivo behavior of these cell populations. After 8 weeks, multilineage donor engraftment was obsewed in these grafts. FISH analysis of the donor cells within the grafts showed that 55.3% and 60.0% of the cells were Ph+. We condude that unfractionated MPB from this patient population is not leukemia-free and that the CD34'Thy-1 +Lit--cell subpopulation, although predominantly enriched for normal HSC, still contains substantial numbers of residual leukemic cells.
We attempted to determine the frequency of normal hematopoietic stem cells (HSC) and contaminating leukemic cells in mobilized peripheral blood (MPB) collected from chronic myeloid leukemia (CML) patients, intolerant of a-interferon or with interferon-resistant disease. A total of 14 MPB samples, six from patients in chronic phase (CP) and eight from patients in accelerated phase or blast crisis (AP/BC) were studied. Cytogenetic analysis of MPB collected from AP/BC patients showed that 100% of the cells were Ph+, whereas cells from four of five CP MPB were Ph-. By contrast, fluorescence in situ hybridization (FISH) analysis of CP MPB showed a mean frequency of 14.7% Ph+ cells, while AP/BC MPB contained 39.2% Ph+ cells. In an attempt to purify normal HSC, subpopulations of the MPB CD34+ cells were isolated based on expression of the Thy-1 antigen (Chnrso). The mean Ph+ cell frequency as determined by FISH within the CD34+Thy-l+ Linand CD34+Thy-I-Lin-populations from CP patients was 19.2% and 33.9%, respectively. In the AP/BC patients, levels of residual leukemic cells were significantly greater with mean Ph+
HRONIC MYELOID LEUKEMIA (CML) is a clonal
C myeloproliferative malignancy that originates at the level of primitive hematopoietic stem cells.',' In a significant proportion of CML patients, allogeneic bone marrow transplantation (BMT) results in prolonged disease-free survival and is likely curative in some patients for at least a certain period of f o l l o w -~p .~~~ Unfortunately, most patients are not suitable for allogeneic BMT due to lack of an appropriate available donor or because of relatively advanced age. McGlave et a16 recently reported the results of a multicenter study that suggests autologous transplantation can prolong the survival of patients with CML. However, the persistence of leukemic cells within the marrow and peripheral blood of patients posttransplantation was evident in a majority of the survivors. 6 Relapse of these patients may result from the persistence of tumor cells within the patients following intensive myeloablative therapy and/or be the result of tumor cells present in the graft. Support for the latter explanation for the CD34+Thy-lfLin-cells as compared with 1 of 133 for the Thy-1-fraction indicating a higher frequency of primitive progenitor cells in the Thy-l+ subpopulation. CD34' cell subsets from two patients were also injected into SClDhu bone assays to determine the in vivo behavior of these cell populations. After 8 weeks, multilineage donor engraftment was obsewed in these grafts. FISH analysis of the donor cells within the grafts showed that 55.3% and 60.0% of the cells were Ph+. We condude that unfractionated MPB from this patient population is not leukemia-free and that the CD34'Thy-1 +Lit--cell subpopulation, although predominantly enriched for normal HSC, still contains substantial numbers of residual leukemic cells.
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has been provided using gene marking to demonstrate that CML cells present in bone marrow autografts can contribute to relapse.' Therefore, elimination or reduction of the number of leukemic cells within autografts might result in an increase in prolonged disease-free survival following autologous transplantation.
Evidence for the presence of normal and Ph+ hematopoietic stem cells (HSC) in the marrow and peripheral blood of CML patients has been reported previously.8-'5 Two recent reports dealing with the examination of primitive hematopoietic progenitors isolated from the marrow of patients with CML in chronic phase (CP) have indicated the presence of cells containing the Ph chromosome that are not expressing the bcr-ab1 fusion product.'"." Such findings may explain the expansion of the leukemic clone at the level of the mature myeloid progenitor without a selective expansion of the primitive CML HSC. Therefore, purification of HSC from CML patients at a stage before expression of the bcr-ab1 transcript could lead to the isolation of autografts containing primarily normal HSC. Verfaillie et all4 have reported the presence of exclusively normal HSC within the HLA-DR lowhegative (DR-) subfraction of CD34+ from early chronic phase CML bone marrow. Leemhuis et all5 using a similar cell population from chronic phase CML marrow have also identified normal HSC, but at a lower frequency. Recently, Kirk et al,'* using fluorescence in situ hybridization (FISH) to detect the Ph chromosome, have reported the enrichment of normal HSC within the CD34+DR-, but not in the CD34+CD38-population of cells isolated from chronic phase CML patients. Together these data indicate that the levels of Ph+ cells within the CD34+DR-population are reduced compared with the CD34+DR+ population, but that these purified populations still contain considerable numbers of leukemia cells.
A number of groups have reported the presence of human HSC within subfractions of CD34+ cells (reviewed in Spangr~de.'~.~'-*~) We have shown previously that the Thy-1 surface marker subsets the CD34+ fraction of fetal BM, adult BM, and mobilized peripheral blood (MPB) and the isolated Thy-l+ subset is highly enriched for HSC.23*24 Purification of CD34+Thy-I+Lin-HSC from the MPB of multiple myeloma patients has been shown to reduce the level of contaminating tumor below the level of detection.** We hoped to determine if purification of these long-term repopulating HSC from the more mature components of the graft in a-interferon resistant or intolerant CML patients would result in a leukemia-depleted HSC graft.
Differential mobilization of normal HSC and tumor cells has also been used to create presumably leukemia-free autografts. Carella et a126 have reported the preferential mobilization of normal HSC rather than Ph' HSC after intensive chemotherapy of interferon-resistant CML patients with idarubicin, etoposide, and cytosine arabinoside (ICE) followed by granulocyte colony-stimulating factor (G-CSF). Ph-leukapheresis products, as determined by cytogenetic analysis, were collected in 60% of patients treated in chronic phase and 20% to 30% of patients in blast crisis (BC) or accelerated phase (AP). In addition, Kantarjian et a12' have shown that following intensive chemotherapy of 38 patients with CML leukapheresis products from 28% of patients were free of leukemia cells. Their report confirmed that the peripheral blood of these patients contains fewer leukemia cells than the marrow. Talpaz et a12* have presented data that suggests the outcome of transplants using these autografts is in part dependent on the percentage of Ph+ and Ph-cells within the autograft. We hypothesized that the combination of preferential mobilization of nonleukemic cells during recovery from intensive chemotherapy of CML patients and purification of normal HSC by means of monoclonal antibody (MoAb) labeling and fluorescence-activated cell sorter (FACS) would lead to a further reduction in the leukemic cell level and permit the isolation of a leukemia-depleted HSC graft.
MATERIALS AND METHODS
Twelve cytogenetically and morphologically confirmed CML patients in CP, AP, or BC were the subject of this study. Informed consent, approved by the Human Subjects Committee at participating centers, was obtained before the performance of these studies. Patients used for this study were ainterferon intolerant or resistant (defined as < 10% cytogenetic response at 6 months and <66% cytogenetic response at 12 months), between the ages of 15 and 60, and had no allogeneic donor available. BM aspirates from the posterior iliac crest were obtained before the administration of chemotherapy and G-CSF. Patients were placed on a mobilization protocol, approved by the Human Subjects Committee at participating centers, as previously described by Carella et Briefly, patients were mobilized with ICE chemotherapy consisting of idarubicin at 8 mg/mz on days 1 to 5 , arabinosylcytosine at 800 mg/m' in 2-hour infusions on days 1 to 5, and etoposide at 150 mg/mz on days 1 to 3. On day 8 postchemotherapy, subcutaneous administration of G-CSF at 5 pgkgld was begun and continued until a total neutrophil count of greater than 1 X 109L was reached for 3 consecutive days. Leukapheresis was initiated when the white blood cell (WBC) count was greater than 0.5 x lo9 celldL and was continued until >5 x 10' mononuclear cellskg were collected. Cytogenetic analysis of BM aspirates and MPB leukapheresis products were performed using standard metaphase cytogenetic techniques in the cytogenetic laboratories in Genova, Italy; Paris, France; Duarte, CA; and Palo Alto, CA.
Slide preparation of unfractionated samples. Leukapheresis samples were centrifuged in a table-top centrifuge for 8 minutes at 900 rpm (200g), 22°C to pellet the cells. Red blood cells were removed by resuspending the cell pellet in 0.84% ammonium chloride lysis solution for 5 minutes at 4°C. Mononuclear cells were isolated by centrifugation and washed once in RPMI supplemented with 10% FBS. Slides were prepared using a cytocentrifuge (Shandon, Pittsburgh, PA). Approximately 1 to 5 x 104 cells in RPMY 10% FBS were added to each sample chamber and centrifuged for 3 minutes at 450 rpm. Slides were removed from the cytocentrifuge and air-dried. The slides were fixed with methano1:acetic acid (3:l) for 15 minutes and allowed to air-dry. Slides were stored at -80°C until use.
Flow cytometry-purified cells were pelleted in 15 mL screw-capped tubes using a table-top centrifuge and washed once with RPMI containing 10 U/mL of heparin (ICN Biomedicals Inc, Aurora, OH). The cells were resuspended in 100 to 200 pL of RPMyheparin for each 20,000 cells. A PAP pen (Research Products International, Mt. Prospect, IL) was used to mark a rectangle on silane-treated slides, and 100 to 200 pL of cell suspension was spread throughout the rectangle. Slides were incubated for 30 to 45 minutes at room temperature (RT) to allow the cells to settle and attach to the slides. Excess liquid was removed by tipping the slides sideways and the slides were air-dried. The slides were fixed with methano1:acetic acid (3:l) for 15 minutes and allowed to air-dry. Slides were stored at -80°C until use.
On the day of hybridization, slides were thawed at RT, refixed with methanokacetic acid (3:1), and air-dried. As a pretreat-
Cytogenetics.
Slide preparation of puriJied samples.
FISH.

VAN DEN BERG ET AL
ment, the slides were incubated in 2X SSC (3 m o m NaCl, 0.3 mol/ L sodium citrate, pH 7.0) for 30 minutes at 37T, followed by dehydration in a series containing ethanol at a concentration of 70%, 90%, and 100% at RT. In some cases, the slides were treated by pepsin (Sigma, St Louis, MO) to improve probe penetrati~n.~' Slides were denatured in 70% formamide/2x SSC for 2 minutes at 72°C followed by dehydration in a series containing ethanol at a concentration of 70%, 90%, and 100% on ice. The CML translocation probe (Oncor, Gaithersburg, MD) consisted of a mixture of digoxigeninlabelled probes for the bcr locus and biotin-labelled probes for the cabl locus. Hybridization was performed according to manufacturer's instruction with minor modifications. The probe was prewarmed for 5 minutes at 37°C before addition to the prewarmed slides. Slides were coverslipped, sealed, and incubated overnight at 37°C in a humidified chamber. The next day, the coverslips were removed, and the slides were washed three times in 50% formamide/2x SSC for 5 minutes each at 43°C followed by two washes in 2 x SSC for IO minutes each at 37°C. A final wash in 0 . 1~ SSC for 5 minutes at 37°C was performed. Before detection, the slides were blocked by incubation in detection staining buffer (DSB = 4 x SSC/O.O5% Tween-20/10% normal rabbit serum [NRS; Vector Laboratories, Burlingame, CAI) for 30 minutes at 37°C. Detection of the bound probe was performed using a two-step immunodetection system. For the first step, a 1:100 dilution of mouse antidigoxigenin MoAb (Boehringer Mannheim, Indianapolis, IN) and a ]:I00 dilution of fluorescein isothiocyanate (FITC) conjugated streptavidin (Vector Laboratories) was made in DSB. Slides were incubated in this mixture for 45 minutes at 37°C followed by three washes in 4X SSC/ 0.05% Tween for 5 minutes each at RT. For the second step, a 150 dilution of rhodamine-conjugated sheep antimouse F(ab')' antibody (Boehringer Mannheim) and a 1:lOO dilution of FITC-conjugated goat antistreptavidin antibody (Vector Laboratories) was made in DSB. Slides were incubated in this mixture for 45 minutes at 37°C followed by three washes in 4X SSC/O.O5% Tween for 5 minutes each at RT. The slides were counterstained with 0.3 pg/mL 4',6-diamino-2-phenylindole (DAPI; Sigma) in 4X SSC/O.O5% Tween for 5 minutes at RT and mounted in Vectashield mounting media (Vector Laboratories). Slides were analyzed with a Nikon photomicroscope equipped with epifluorescence and lOOX/I , 257 oil PlanNeofluoar objectives. Cells were visualized using a triple-band pass filter (Chroma, Brattlebro, VT). Images were taken using a C * Imaging 1280 analysis system (Compix Inc, Mars, PA) using a CCD camera (Photometrics, Tucson, AZ), automated stage and filter wheel (LUDL, Hawthome, NY), and SIMPLE software (Compix Inc). Individual images were taken through DAPI, FITC, and Rhodamine band-pass filters (Chroma) in combination with neutral density filters, pseudocolored blue, green, and red, respectively, and layered on top of one another to give the final color image. The image was digitally stored in tagged image file format (TIFF) and was imported into Microsoft Imager (Microsoft, Redmond, WA) for adjustment of the brightness and contrast of the image such that the final print image matched the original video image. Print images were made from negatives obtained by placing the digital image onto a film negative using a film recorder. All analyses were performed using cells with good nuclear morphology and complete, nonoverlapping nuclei. A cell was scored Ph-if two distinct red and two distinct green signals were visible within a nucleus. A cell was scored Ph' if it contained one distinct red signal, one distinct green signal, and one distinct yellow signal representing the coincidence of a red and green signal. In addition, a cell was scored Ph' if it contained two distinct red signals and two distinct green signals with one red signal and one green signal in close juxtaposition. All other cells that contained fewer signals were not scored as Ph+ or Ph-, but were used to calculate the hybridization frequency, which ranged from 90% to 95% for this study. Any cells that contained additional signals consistent with the presence of more than one Ph+ chromosome were scored as Ph+. Hybridization and analysis of several normal blood samples as controls resulted in a Ph+ frequency between 1.0% and 1.4%, which represents the background associated with the FISH technique for this application.
Cells were resuspended in phosphate-buffered saline (PBS) 0.02% gamimmune (Miles Inc, Elkhart, IN) for 10 minutes on ice and then stained with reagents prepared by Systemix' Product Development and Operations divisions:
Sulforhodamine 101 conjugated anti-CD34 F(ab'), , 2.5 pg/mL (Tuk3 from A. Ziegler, University of Berlin, Berlin, Germany), biotinylated anti-Thy-1 (GM201 from Dr W. Rettig, Ludwig Cancer Institute, New York, NY), fluoresceinated anti-CD14, 1 pg/ml (Tuk4 from A. Ziegler), fluoresceinated anti-CD15, 1 &mL (Tuk9 from A. Ziegler). After 20 minutes on ice, cells were removed as a control, and streptavidin (ProZyme Inc, El Cerrito, CA) was added to a final concentration of 100 pg/mL for an additional 20 minutes on ice. After washing the cells in SB, biotinylated R-phycoerythrin (PE; Martek Bioscience Inc, Columbia, MD) was added at 10 pg/mL to both tubes and cells incubated for a further 20 minutes on ice. After a final wash in SB, cells were resuspended in 1 pg/mL propidium iodide (Boehringer Mannheim) and sorted on the FACSTAR Plus cell sorter (Becton Dickinson) equipped with dual argon ion lasers, the primary emitting at 488 nm and a dye laser (Rhodamine 6G) emitting at 600 nm (Coherent Innova 90, Santa Clara, CA). MPB CD34'Lin-(Lin-= CD14 and CD15 negative populations) cells were divided into Thy-I' and Thy-1-cell subsets, setting the Thy-1' gate so as to contain < I % of CD34' cells stained with the primary control antibodies. Cell populations sorted were from the lymphoblastoid region (RI) after removal of cells with high propidium iodide uptake and electronically gating out Lin+ cells (R2).
The CAFC assay was performed as previously rep~rted.'~ Briefly, SySl mouse BM stromal cells were plated in Whitlock-Witte Media3' in wells of polystyrene Rat-bottom 96-well plates (Coming, Coming, NY), and allowed to form a confluent adherent layer. After 1 to 2 weeks, sorted cells were plated onto confluent SySl cells at limiting dilution (100 to 1 cells/well, 24 wells per concentration) in long-term culture media (1:I IMDMI RPMI; JRH Biosciences) containing 10% FBS, 50 U/mL penicillin, 50 pg/mL streptomycin, 2 "0% glutamine, 1 mmol/L sodium pyruvate (JRH Biosciences) and m o m 2-mercaptoethanol (Sigma), in the presence of purified interleukin-6 (IL-6) at 10 ng/ mL and leukemia inhibitory factor (LIF) at 50 ng/", provided by Sandoz Inc (Basel, Switzerland). Cultures were replenished weekly with medium containing the same growth factors. Cobblestone areas consisting of >50 blast-like cells (uniform refractal agranular cells in close association) were enumerated after 5 weeks of incubation. The frequency of CAFC was calculated by the cell number at which 37% of the wells show no growth of cobblestone areas, using regression analysis, with 95% statistical precision. 33 Immunodeficient C.B-17 scid/scid mice were used as recipients of human fetal tissues. Fetal tissues were obtained with informed consent, according to state and federal regulations. Mice were bred under specific pathogen-free conditions in the Systemix animal facility and were transplanted at 6 to 8 weeks of age with human fetal bone fragments. The grafts were allowed to vascularize and establish in the murine surrogate host for 8 weeks before being used. Mice received a single dose (350 rads) of whole body irradiation from a '"Cesium source (JL Shepherd and Associates, San Femando, CA) immediately before the injection of HLA-mismatched donor cell populations. Sorted cells were injected directly into the bone grafts in a 10-pL volume, using a Hamilton syringe. The bone grafts were removed 8 weeks postcell injection, and the cellular contents were harvested by flushing with PBS/O.2% bovine serum albumin (BSA;
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RESULTS
Cytogenetic and FISH analysis of CML patient samples. BM aspirates and MPB specimens from 12 CML patients were analyzed by standard metaphase cytogenetics for the presence of the Ph chromosome. The results from six samples obtained from patients in chronic phase and eight samples from patients in AP or BC are summarized in Table 1 .
Because the findings were similar for samples from patients in AP or BC, samples from either stage of disease are grouped together. A consistent finding of 100% Philadelphia chromosome positive (Ph+) cells in bone marrow aspirates (preBM) was found in samples from patients in both CP and APBC before high dose chemotherapy. Analysis of the percentage of Ph+ cells within the MPB collects showed a distinct difference in the levels of cytogenetically detectable leukemia cells between the two patient populations. Samples from patients in CP contained no, or a minor population of, detectable Ph+ cells with a mean of 6%, while samples from patients in AP/BC were 100% Ph+. Only one MPB sample from a CP patient contained a considerable number of Ph+ cells (30%), while the remaining four samples were negative for Ph+ cells.
These results reflect the level of leukemia cells within the dividing cell population of these patient samples. To further analyze the extent of leukemia cell contamination within the interphase cell population of the MPB samples, FISH analysis was performed using probes for the bcr and c-ab1 loci. The results of FISH analysis on MPB samples also show a distinct difference in the levels of Ph+ cells detected within the two patient populations and are summarized in Table 1 . The mean level of Ph+ cells in the MPB samples from patients in CP and APBC were 14.7% and 39.2%, respectively. T-test analysis of the original data indicated a statistical difference between the results for the two patient populations (P = .005). Several samples from patients in CP were negative by cytogenetic analysis of metaphase spreads, but contained from 14.9% to 23.0% Ph+ cells by interphase FISH analysis. In one sample from a CP patient (Table 1 ; chronic phase sample #3), a 1.2% Ph+ frequency was found. This frequency of Ph+ cells is within the background of the assay and cannot be considered positive by FISH. The frequency of Ph' cells within samples from patients in APBC was 100% by metaphase cytogenetics, but ranged from a low of 7.1 % to a high of 62.1 % as measured by interphase FISH.
Flow cytometric isolation and in vitro activity of subpopulations of CD34+Lin-cells from the MPB of CML patients.
The CD34+Lin-cell population in the MPB of CML patients was subdivided using the Thy-1 cell surface marker into Thy-1-positive (Thy-l+) and Thy-I-negative (Thy-I-) subpopulations. Figure 1A through C shows the gating scheme used during the purification of the subpopulations from a CP patient sample. Approximately 10% of the purified sample was used for reanalysis to determine sort purity based on the original gating scheme (Fig 1D and E) . The mean purity of the CD34+Thy-l+Lin-cell populations was 83% with a range of 74% to 92%, while the mean purity for the CD34Thy-l-Lin-population was 73% and a range of 54% to 89%. The lower purity of the CD34+Thy-l-Lin-populations was primarily due to an increase in the number of CD34-negative cells within this subpopulation (data not shown). The purity reported for each cell population reflects the minimum purity, based on reanalysis using the original sort gates.
To determine the primitive progenitor frequency in the purified subpopulations, a proportion of the isolated cells were assayed for cobblestone area forming cells (CAFC). The results from the Thy-l+ and Thy-1-subpopulations of CD34+Lin-cells purified from the MPB of CML patients are summarized in Table 2 . In each sample the Thy-l+ subpopulation contained the highest frequency of CAFC ranging from 1 of 7 to 1 of 126 with a mean of 1 of 19. The Thy-1-subpopulation still contained considerable CAFC activity with a mean frequency of 1 of 133.
FISH analysis of the Ph' frequency within the pur$ed CD34'Lin-subpopulations. To determine the levels of Estimate of the fraction of cells in the input population that give rise to cobblestone areas. leukemic cells within the CD34'Lin-subpopulations. FISH analysis was performed on the purified cells. Table 3 summarizes the results for the Thy-I' and Thy-1 -subpopulations of the CD34'Lin-cells isolated from CP patient samples.
The mean frequency of Ph' cells in the Thy-I ' and Thy-Isubpopulations was 19.2% and 33.9%. respectively. In the overwhelming majority of samples (samples 1 to 5 , Table  3 ), the frequency of Ph' cells within the Thy-I + subpopulation was lower than in the Thy-I-subpopulation. The Ph' cell frequency range was from 6.5% to 33.08 for the Thy- FISH analysis of the subpopulations of CD34'Lin-cells from CML patients in AP/BC are also summarized in Table  3 . The mean frequency of Ph' cells within the Thy-I' and Thy-I -subpopulations was 59.2% and 72.7%. respectively. In most AP/BC patient samples (samples 1 to 7, Table 3 ). the level of Ph' cells was greater in the Thy-I-subpopulation compared with the Thy-I+. The frequency of Ph' cells ranged from 28.0% to 78.0% for the Thy-I ' subpopulation and ranged from 48.7% to 88.0% for the Thy-I -subpopulation.
Statistical analysis of the data in Table 3 indicates that these findings are consistent with a significant difference in the levels of leukemic cells observed within the purified CD34+Lin-subpopulations from patients in CP compared with patients in AP/BC. The difference in Ph+ cell frequency between the CP and AP/BC patient samples is statistically significant for the Thy-1' and Thy-1-subpopulations (P = .O005 and P = .0029, respectively). In addition, the difference in Ph+ cell frequency between the Thy-l+ and Thy-1-subpopulations from CP patient samples is statistically significant (P = .034). In contrast, the difference in Ph+ cell frequency between the Thy-1+ and Thy-1-subpopulations from AP/BC patient samples is not statistically significant ( P = .133).
Engrafhnent of CD34+ subpopulations from CML patient samples in the SCZD-hu bone model. The ability of purified populations from the MPB of CML patients to repopulate marrow was tested in the SCID-hu bone assay. In two separate experiments, the CD34' cells from a CP patient or the Thy-l+ subpopulation of CD34+Lin-cells from an AP patient were injected into human fetal bone implanted in SCID mice. Engraftment of the injected cells after 8 weeks was demonstrated in both experiments by the presence of donor specific HLA-positive cells (Fig 2A) . Table 4 summarizes the engraftment results for the two experiments. In experiment one, a majority of the grafts (5 of 8) injected with at least 500,000 cells contained significant levels of donor cells 8 or 9 weeks after injection. In contrast, none of the 10 grafts injected with only 100,OOO CD34' cells contained detectable levels of donor cells. In the second experiment, most grafts (6 of 8) contained significant levels of donor cells 8 weeks after injection, even when as few as 50,000 cells were injected into the graft (4 of 6). To determine the levels of leukemic cells within the grafts, donor cells were isolated by flow cytometry and analyzed by FISH for the presence of Ph+ cells. The results for both experiments are also summarized in Table 4 . Ph+ cells were detected in both samples indicating that primitive CML progenitor cells within the injected cell population will engraft in the SCID-hu bone assay. In addition, the level of Ph+ cells was considerably less than loo%, indicating that the normal stem cells within the 50,000 injected cells were also able to engraft and proliferate.
To better understand the nature of marrow repopulation and engraftment of the injected cells, analysis of the donorderived cells obtained from the SCID-hu mice was performed. The results of flow cytometry analysis using antibodies to the donor-specific HLA and antibodies to CD19, CD33, and CD34 (Fig 2B through D) are summarized in Table 5 . Of the donor-derived cells from the six positive grafts from experiment 2, 3.7% were donor-derived CD19' B cells, 82.3% CD33+ myeloid cells, and 29.3% CD34+ cells. Results of analysis of the host cells are also shown in Table 5 . There was an unusually high percentage of CD33+ myeloid cells present within the donor populations compared with the host populations. The mean CD33+ frequency in the donor population was 82.3%, while the frequency was 7.3% in the host population. In addition, the mean CD19+ frequency was 74.9% in the host and 3.7% in the donor populations. Because the levels of CD19' cells are above 1% for most grafts analyzed, the presence of CD19+ cells in the donor population does signify multilineage engraftment.
DISCUSSION
The current study was initiated to determine the level of normal HSC within subpopulations of CD34+Lin-cells isolated from the MPB of CML patients. These studies were directed towards ultimately identifying a leukemia-free autograft for CML patients. Detection of leukemic cells was performed using a two-color FISH analysis of patient samples and compared with results found by standard cytogenetics. The levels of leukemic cells within the HSC population of CD34+Thy-l+Lin-cells were analyzed and the marrow repopulating ability of this population in the SCID-hu bone model was assessed.
The presence of a Ph chromosome is diagnostic for CML. not detected by cytogenetic analysis. This is primarily due to the fact that cytogenetic analysis is restricted to cells that are actively dividing in a sample population. Because of the quiescent nature of the purified HSC population, it is impossible to determine the Ph content of these populations by cytogenetics."-39 FISH analysis, as outlined in this study, is performed directly on the purified cell populations in the absence of further culture or manipulation. In addition, from the FISH analysis of the purified samples, it is clear that the levels of contaminating tumor cells are significantly different in the two patient populations. Samples from patients in CP We found that subfractionation of the CD34+Lin-population from the MPB of CML patients resulted in significant levels of residual leukemia cells in the CD34+Thy-l+Lin-population, with mean Ph+ frequencies of 19.2% and 59.2% for the CP and AP/BC samples, respectively. Samples from patients in CP contained significantly fewer leukemia cells in unpurified (P = .005), CD34+Thy-l+Lin-purified (P = .Oms), and CD34+Thy-l-Lin-purified (P = .0029) cell populations compared with samples from patients in AP or BC. From these data, one would anticipate that the reduction of Ph+ cells resulting from the isolation of the CD34+Thy-1 +Lin-subpopulation could result in a potentially superior autograft.
Results from the in vitro and in vivo characterization of the stem cell activity of these purified cell populations indicate that a population of normal HSC are present in the MPB of CP CML patients. Long-term CAFC analysis of subpopulations of CD34+ cells indicates the presence of pluripotent progenitor cells within the CD34+Thy-1 +Lin-population of MPB collected from both CP and AP/BC CML patients. The CAFC frequency of the CD34+Thy-l+Lin-population was similar to that detected in the MPB collected from patients with a variety of malignan~ies.'~ Although the frequency of CAFC is lower in the CD34+Thy-l-Linpopulation, a significant number of CAFC are present in this cell population, the majority of which are likely due to leukemic stem cells. In vivo engraftment of the purified cell populations in the SCID-hu bone assay lends further support to the existence of both normal and leukemic HSC within these populations. In both experiments, when sufficient cells were injected in each graft, a majority of the grafts showed multilineage donor engraftment after 8 weeks.
These studies indicate that the SCID-hu bone assay can be used to assess the engraftment potential of purified HSC populations. Elimination or reduction of the leukemic burden will rely on further attempts to subfractionate the CD34+ population using additional stem cell markers or elimination of the tumor using markers found on a majority of leukemic cells. Reports of autologous transplantation of CML patients using unfractionated MPB cells indicate that many patients are in cytogenetic remission for a limited period of time following a u t o t r a n~p l a n t a t i o n .~~~~~~'~~ Because these grafts must certainly contain leukemic cells, it is hopeful that further reductions in the levels of reinfused tumor cells may result in prolonged periods of remission. 
